EP2758031A1 — Ophthalmic gel compositions
Assigned to Bausch and Lomb Inc · Expires 2014-07-30 · 12y expired
What this patent protects
A suspension comprising an ophthalmic active that has a solubility in water at 25° C and a pH of 7 of less than 0.1 times the concentration of the active in mg/mL in the suspension, the ophthalmic active suspended in a formulation vehicle. The formulation vehicle comprises a ligh…
USPTO Abstract
A suspension comprising an ophthalmic active that has a solubility in water at 25° C and a pH of 7 of less than 0.1 times the concentration of the active in mg/mL in the suspension, the ophthalmic active suspended in a formulation vehicle. The formulation vehicle comprises a lightly cross-linked carboxy-containing polymer and a concentration of ionic salt components to provide the suspension with a calculated ionic strength of less than 0.1. The suspension has the following rheological properties, G' > G" and a suspension yield value of greater than 1 Pa. Also, upon addition of 30 inL of the suspension to a volume of 6 mL to 12 mL of simulated tear fluid, the resulting tear mixture transitions to a liquid form wherein, G" > G' and the tear mixture has a yield value of less than 0.1 Pa.
Drugs covered by this patent
- Lotemax (LOTEPREDNOL ETABONATE) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.